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Abstract
Background
The clinical presentation ofM. ulcerans disease and the safety and effectiveness of treat-
ment may differ in elderly compared with younger populations related to relative immune
defficiencies, co-morbidities and drug interactions. However, elderly populations withM.
ulcerans disease have not been comprehensively studied.
Methodology/Principal Findings
A retrospective analysis was performed on an observational cohort of all confirmedM.
ulcerans cases managed at Barwon Health from 1/1/1998-31/12/2014. The cohort included
327 patients; 131(40.0%)65 years and 196(60.0%) <65 years of age. Patients65 years
had a shorter median duration of symptoms prior to diagnosis (p<0.01), a higher proportion
with diabetes (p<0.001) and immune suppression (p<0.001), and were more likely to have
lesions that were multiple (OR 4.67, 95% CI 1.78–12.31, p<0.001) and WHO category 3
(OR 4.59, 95% CI 1.98–10.59, p<0.001). Antibiotic complications occurred in 69(24.3%)
treatment episodes at an increased incidence in those aged65 years (OR 5.29, 95% CI
2.81–9.98, p<0.001). There were 4(1.2%) deaths, with significantly more in the age-group
65 years (4 compared with 0 deaths, p = 0.01). The overall treatment success rate was
92.2%. For the age-group65 years there was a reduced rate of treatment success overall
(OR 0.34, 95% CI 0.14–0.80, p = <0.01) and when surgery was used alone (OR 0.21, 95%
CI 0.06–0.76, p<0.01). Patients65 years were more likely to have a paradoxical reaction
(OR 2.06, 95% CI 1.17–3.62, p = 0.01).
Conclusions/Significance
Elderly patients comprise a significant proportion ofM. ulcerans disease patients in Austra-
lian populations and present with more severe and advanced disease forms. Currently rec-
ommended treatments are associated with increased toxicity and reduced effectiveness in
elderly populations. Increased efforts are required to diagnoseM. ulcerans earlier in elderly
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populations, and research is urgently required to develop more effective and less toxic treat-
ments for this age-group.
Author Summary
Mycobacterium ulcerans is an infection that can affect all age-groups. It causes necrosis of
skin and soft-tissue often resulting in severe outcomes and long-term disability. However,
due to the majority of infections worldwide occurring in children and young adults, there
is a paucity of information available in elderly patients. It is important that elderly patients
are not neglected as the clinical presentation and treatment outcomes may differ signifi-
cantly from younger patients related to relative immune defficiencies, co-morbidities and
increased potential for drug interactions. We specifically examined patients with M. ulcer-
ans disease aged 65 years and showed that they comprise a significant proportion of
patients affected in Australian populations. They present with more severe and advanced
disease forms, and suffer from increased toxicity and reduced effectiveness of the currently
recommended treatments. Therefore, our study demonstrates that increased efforts are
required to diagnoseM. ulcerans disease earlier in elderly populations, and that research is
urgently required to develop more effective and less toxic treatments for this age-group.
Introduction
Mycobacterium ulcerans (M. ulcerans) is an infection that causes necrotizing lesions of skin
and subcutaneous tissue. The majority of cases are reported from west and central Africa, but
unlike Africa where the disease occurs mainly in children[1,2], in south-eastern Victoria, Aus-
tralia it occurs mainly in adults with a large proportion aged> 50 years.[3] Reported rates of
disease in Australian populations are up to 7 times higher in those55 years of age[4]. Current
M. ulcerans treatment guidelines recommend combined antibiotics for 8 weeks with surgery as
an adjunctive treatment[5,6].
The clinical presentation ofM. ulcerans disease (Buruli ulcer), as well as the safety and
effectiveness of treatment, may differ in elderly compared with younger populations. It is
known that immune function reduces with senescence, and as the immune system plays a vital
role in the control ofM. ulcerans[7,8], this may lead to an increase in the incidence and sever-
ity of disease as well as reduced effectiveness of treatment. There may also be altered health-
seeking behaviours in older people who may find accessing healthcare more difficult or neglect
skin lesions, or for whom there is a potentially increased prevalence of alternative causes of
ulceration (eg venous disease) resulting in misdiagnosis. These aforementioned issues could
lead to delays in diagnosis with increased disease severity. Furthermore, increased rates of co-
morbidities in elderly patients may adversely affect immune function, but may also lead to
increased drug interactions and the potential for increased toxicity associated with antibiotic
treatment[9].
In our practice we have observed significant numbers of elderly patients developingM.
ulcerans disease. Our earlier published experience has suggested that populations older than 60
years of age may have had increased prevalence of multipleM. ulcerans lesions at presentation
[3], reduced rates of treatment success with surgical treatment[10], and increased rates of anti-
biotic related paradoxical reactions[11]. However, populations aged65 years withM. ulcer-
ans have not been comprehensively studied. We therefore undertook to describe in an
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Australian cohort the proportion of patients aged65 years affected byM. ulcerans and com-
pare them with younger patients with respect to their clinical presentation, and the safety and
effectiveness of treatment.
Methods
A retrospective analysis was performed on data from a prospectively collected cohort of all
confirmedM. ulcerans cases managed at Barwon Health from 1/1/1998-31/12/2014. AM.
ulcerans case was defined as the presence of a lesion clinically suggestive ofM. ulcerans plus
any of (1) a culture ofM. ulcerans from the lesion, (2) a positive PCR from a swab or biopsy of
the lesion, or (3) histopathology of an excised lesion showing a necrotic granulomatous ulcer
with the presence of acid-fast bacilli (AFB) consistent with acuteM. ulcerans infection. Lesion
size was determined by measuring the extent of lesion induration with a ruler and aWHO cate-
gory was assigned according to published definitions.[5] Elderly age was defined as65 years
in line with the accepted definition for most developed countries[12].
Drug dosages for adults included rifampicin 10 mg/kg/day (up to a maximum of 600 mg
daily), ciprofloxacin 500 mg twice daily, moxifloxacin 400 mg once daily, clarithromycin 7.5
mg/kg twice daily (up to 500 mg twice daily) and ethambutol 15 mg/kg/day. A complication of
medical therapy was defined as an adverse event attributed to an antibiotic that required its ces-
sation. In cases where it was not possible to determine which antibiotic of a combination was
responsible for the complication, both antibiotics were attributed with a complication. Immune
suppression was defined as current treatment with immunosuppressive medication (eg. pred-
nisolone) or active malignancy.
Treatment failure was defined as patients developing disease recurrence within 12 months
of initiating treatment. Recurrence was defined as a new lesion appearing in the wound, locally,
or another part of the body that met the case definition forM. ulcerans disease within 12
months of initiating treatment. Paradoxical reactions were defined by the presence of one or
both of the following features: a) clinical: an initial improvement on antibiotic treatment in the
clinical appearance of aM. ulcerans lesion followed by deterioration of the lesion or its sur-
rounding tissues, or the appearance of a new lesion(s), and b) histopathology examination of
excised tissue from the clinical lesion showing evidence of an intense inflammatory reaction
consistent with a paradoxical reaction[11].
Data analysis
Data was collected prospectively using Epi-info 6 (CDC, Atlanta) and analysed retrospectively
using STATA 12 (StataCorp, Texas, USA). Outcome data were censored at the time of death,
disease recurrence or after 12 months of follow-up from initiation of antibiotics. Categorical
variables were compared using 2x2 tables and the Chi-squared test. Medians of non-parametric
variables were compared using the Wilcoxon rank sum test. Odds ratios were calculated using
the Mantel-Haenszel test.
Ethics
This study was approved by the Barwon Health Human Research and Ethics Committee. All
previously gathered human medical data were analysed in a de-identified fashion.
Results
There were 327 patients treated forM. ulcerans at Barwon Health between 1/1/1998-31/12/
2014 and all were included in the study. The median patient age was 58 years (IQR 35–74
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years); 131 (40.0%) were65 years and 196 (60.0%) were<65 years. 165 (50.5%) were male
and 162 (49.5%) female.
Three hundred and eight (94.2%) patients had 1M. ulcerans lesion, 10 (3.1%) had 2 lesions,
6 (1.8%) had 3 lesions, 1(0.3%) had 10 lesions and 2 (0.6%) had 13 lesions. 84.9% of lesions
were ulcerative and 79.9% were classified as WHO category 1. The median duration of symp-
toms prior to diagnosis was 42 days (IQR 28–70 days). (Table 1)
Comparison of baseline characteristics between age-groups
There were some significant differences in baseline characteristics between the age-groups.
(Table 1) Patients in the age-group65 years were less likely to be male (OR 0.60, 95% CI
0.38–0.94, p = 0.02), the median duration of symptoms prior to diagnosis was significantly
shorter (35 compared to 42 days, p<0.01), and there was a higher proportion of patients with
diabetes (p<0.001) and immune suppression (p<0.001).
Clinical
Patients in the age-group65 years were more likely to have lesions that were multiple (OR
3.49, 95% CI 1.26–9.54, p<0.01) and classified as WHO category 3 compared with category 1
and 2 combined (OR 4.89, 95% CI 1.95–12.25, p<0.001). They also had a higher proportion of
Table 1. Baseline patient characteristics stratified by age-group.
Overall Age 65 (n = 131) Age < 65 (n = 196) p-value*
Sex (n = 327)
male 165 (50.5) 56 (42.8) 109 (55.6) 0.02
female 162 (49.5) 75 (57.3) 87 (44.4)
WHO category (n = 298)
1 238 (79.9) 89 (74.2) 149 (83.7) <0.01
2 33 (11.1) 11 (9.2) 22 (12.4)
3 27 (9.1) 20 (16.7) 7 (3.9)
Type of initial lesion (n = 325)
Ulcer 276 (84.9) 108 (83.1) 168 (86.2) 0.18
Nodule 19 (5.9) 7 (5.4) 12 (6.2)
Plaque 3 (1.2) 0 (0) 3 (1.5)
Oedema 27 (8.3) 15 (11.5) 12 (6.2)
Median duration of symptoms (n = 312) (days) 42 (IQR 28–70) 35 (21–60) 42 (28–70) p<0.01
Number of lesions (n = 327)
one 308 (94.2%) 118 (90.1) 190 (96.9) <0.01
Multiple 19 (5.8%) 13 (9.9) 6 (3.1)
Site of initial lesion (n = 327)
Upper limb 114 (34.9) 48 (36.6) 66 (33.7) 0.08
Lower limb 203 (62.0) 80 (61.1) 127 (64.8)
Trunk 7 (2.1) 0 (0) 3 (1.5)
Head 3 (0.9) 3 (2.3) 0 (0.0)
Joint 129 (39.4) 54 (41.2) 75 (38.3) 0.59
Co-morbidities
Diabetes (n = 327) 28 (8.6) 20 (15.3) 8 (4.1) <0.001
Immune suppression (n = 327) 28 (8.6) 22 (16.8) 6 (3.1) <0.001
* Comparing age 65 to age <65 years.
doi:10.1371/journal.pntd.0004253.t001
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oedematous compared to non-oedematous lesions (11.5% compared with 6.2%, p = 0.09).
(Table 1)
Treatment
Two hundred and eighty (85.6%) patients received antibiotic treatment for a median of 56 days
(IQR 49–83 days). 115 (87.8%) of those 65 years received antibiotics and 165 (84.2%) of
those< 65 years received antibiotics (p = 0.97).
There were 284 antibiotic treatment episodes in 280 patients (4 patients received a second
antibiotic course—three due to disease recurrence, and 1 for a late paradoxical reaction). Initial
antibiotic combinations used were rifampicin/ciprofloxacin in 162 (57.0%), rifampicin/clari-
thromycin in 95 (33.4%), rifampicin/moxifloxacin in 8 (2.8%), rifampicin/clarithromycin/eth-
ambutol in 6 (2.1%), clarithromycin/ciprofloxacin in 3 (1.1%) and other varied combinations
in 10 (3.5%) treatment episodes.
Overall 69 (24.3%) antibiotic treatment episodes were associated with a complication severe
enough to require cessation of at least one antibiotic. There was an increased incidence of anti-
biotic complications in those aged 65 years compared with those aged<65 years (OR 5.29,
95% CI 2.81–9.98, p<0.001).
Including antibiotics commenced as second-line treatment following cessation of one or
more of the initial antibiotics due to complications, 276 (97.5%) treatment episodes included
rifampicin, 174 (61.5%) ciprofloxacin, 127 (44.9%) clarithromycin, 13 (4.6%) ethambutol, 10
(3.5%) moxifloxacin and 9 (3.2%) amikacin. Rifampicin was associated with complications in
47 (17.0%) treatment episodes in which it was used, and this was more common in those
aged 65 years compared to< 65 years (OR 4.87, 95% CI 2.36–10.07, p<0.001). (Table 2, Fig
1) Ciprofloxacin was associated with complications in 32 (18.4%) treatment episodes in which
it was used, and this was more common in populations 65 years (OR 2.92, 95% CI 1.26–6.75,
p<0.01). Clarithromycin was associated with complications in 24 (18.9%) treatment episodes
in which it was used, and this was increased in populations 65 years (OR 3.38, 95% CI 1.30–
8.78, p<0.01). (Table 2, Fig 1)
The specific complications associated with each antibiotic are listed in Table 3. In 11
patients hospitalization was required to manage the antibiotic complication; 9/49 (18%) in
those65 and 2/20 (10%) in those<65 years (OR 2.03, 95% CI 0.39–10.55, p = 0.39).
210 (64.2%) patients had surgery; More patients in the 65 years age-group had surgery
compared to the< 65 years age-group [92 (70.2%) compared to 118 (60.2%), (p = 0.06)]. 62
(29.5%) had surgery alone and 148 (70.5%) had surgery plus antibiotics. There was no differ-
ence in the proportions who had surgery alone between the age-groups (p = 0.96).
Table 2. Antibiotic complications.
Antibiotic Overall (n,%) Age  65 years (n,%) Age <65 years (n,%) p-value* OR (95% CI)*
Rifampicin 47/276 (17.0) 34/114 (29.8) 13/162 (8.0) <0.001 4.87 (2.36, 10.07)
Ciproﬂoxacin 32/174 (18.4) 22/83 (26.5) 10/91 (11.0) <0.01 2.92 (1.26, 6.75)
Clarithromycin 24/127 (18.9) 15/49 (30.6) 9/78 (11.5) <0.01 3.38 (1.30,8.78)
Moxiﬂoxacin 3/10 (30.0) 3/5 (60.0) 0/5 (0.0) <0.05 -
Amikacin 3/9 (33.0) 2/6 (33.3) 1/3 (33.3) 1.0 1.00 (0.04–22.61)
Ethambutol 5/13 (38.5) 3/7 (42.9) 2/6 (33.3) 0.74 1.50 (0.14–16.0)
All antibiotics 69/284 (24.3) 49/117 (41.9) 20/167 (12.0) <0.001 5.29 (2.81,9.98)
* Comparing age 65 to age <65 years.
doi:10.1371/journal.pntd.0004253.t002
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Outcomes
Treatment outcomes for firstM. ulcerans lesions could be determined for 323 (98.8%) patients;
2 were lost to follow-up, 1 was transferred out, and 1 had an unclear outcome. At the time of
submission, 300 (92.9%) had their outcomes determined after 12 months of follow-up and 23
(7.1%) patients after 9 months of follow-up.
There were 4 (1.2%) deaths (Table 4). The median age of those who died was 91.5 years
(IQR 71.5–94.5 years), with significantly more deaths in the age-group 65 years compared to
the age-group< 65 years [4 (3.1%) compared to 0 (0.0%), p = 0.01]. Only one of the deaths
(#2) was felt to be directly attributable toM. ulcerans infection as a result of skin sepsis and sec-
ondary decompensated cardiac failure.
For the remaining 319 patients, the overall treatment success rate was 92.2% (Table 5); there
was a reduced rate of treatment success in the age-group 65 years compared to the age-
group<65 years (OR 0.34, 95% CI 0.14–0.80, p<0.01). There was a significantly reduced
Fig 1. Comparison of antibiotic complications between age-groups65 and <65 years.
doi:10.1371/journal.pntd.0004253.g001
Table 3. Specific complications associated with individual antibiotics for all ages combined.
Rash GIT Hepatitis Renal Blood Tendonitis Eye Neurological*
Rifampicin (n = 47) 13 26 14 2 1# 0 0 0
Ciproﬂoxacin (n = 32) 7 19 9 2 0 6 0 0
Clarithromycin (n = 24) 6 16 5 0 0 0 0 0
Moxiﬂoxacin (n = 3) 0 2 1 0 0 0 0 0
Ethambutol (n = 5) 0 3 0 0 0 0 2 0
Amikacin (n = 3) 0 0 0 0 0 0 0 3
GIT: gastrointestinal intolerance;
*ataxia or deafness;
# thrombocytopenia
doi:10.1371/journal.pntd.0004253.t003
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treatment success rate for the age-group 65 years when surgery was used alone (OR 0.21,
95% CI 0.06–0.76, p<0.01). Rates of treatment success for surgery plus antibiotics or antibiot-
ics alone were similar between the age-groups. (Table 5)
67/275 (24.4%) patients experienced antibiotic-associated paradoxical reactions; 36 (32.4%)
patients 65 years and 31 (18.9%) patients< 65 years. Patients 65 years were significantly
more likely to have a paradoxical reaction compared with those< 65 years (OR 2.06, 95% CI
1.17–3.62, p = 0.01). This was independent of the WHO category of the lesion (42% v 22% for
category 1, 56% v 44% for category 2 and 60% v 50% for category 3 when comparing age65
to<65 years).
Discussion
In describing a large cohort of patients aged65 years, we have studied for the first time this
unique population withM. ulcerans disease. Cohorts described from Africa, where mostM.
ulcerans cases are reported, mainly involve children with few numbers of patients aged65
years[1,2]. Additionally, studies reported from Australia have focused on cohorts across all
age-groups[3,13,14]. This study therefore provides important new information pertaining to
the epidemiology, clinical characteristics, treatment and outcomes in elderly populations.
Patients aged65 years represent an important subgroup in our cohort withM. ulcerans
disease comprising two out of every 5 patients. Previous reports suggest that they may have an
increased incidence of disease[4]. Additionally, our study suggests that they have more
Table 4. Patient characteristics of those who died following commencement of MU treatment.
Patient
#
Age Sex Year of
diagnosis
Type of MU
lesion
Site of
MU
lesion
WHO
category
MU lesion
Co-morbidities MU treatment Cause of
death
Time of death
after start of
treatment
(days)
1 94 F 2005 Ulcer Wrist 1 Nil 52 days Rif/Cla.
Surgical
excision and
SSG.
CVA 52
2 89 F 2008 Oedematous Hand 3 Nil 5 days Rif/Cip.
Surgical
excision.
CCF, sepsis 5
3 70 F 2013 Oedematous Leg 3 CLD, long-term
prednisolone
treatment
71 days Rif/Cla Respiratory
failure
186
4 95 F 2014 Oedematous Knee 2 Carcinoma breast 67 days Rif/Cp CVA 152
F = female; CLD = chronic lung disease; MU = Mycobacterium ulcerans; CVA = cerebrovascular accident; CCF = congestive cardiac failure;
Rif = rifampicin; Cla = clarithromycin; Cp = ciproﬂoxacin; SSG: split skin graft
doi:10.1371/journal.pntd.0004253.t004
Table 5. Treatment success for first MU lesions.
All patients (n,%) Age  65 years (n,%) Age <65 years (n,%) p-value* OR (95% CI)*
All treatments 294/319 (92.2) 110/126 (87.3) 184/193 (95.3) <0.01 0.34 (0.14, 0.80)
Surgery alone 40/61 (65.6) 12/26 (46.2) 28/35 (80.0) p<0.01 0.21 (0.06, 0.76)
Surgery + antibiotics 144/145 (99.3) 63/64 (98.4) 81/81 (100) 0.44 0.00 (0.00–13.8)
Antibiotics alone 109/111 (98.2) 35/36 (97.2) 74/75 (98.7) 0.55 0.47 (0.01–17.91)
* Comparing age 65 to age <65 years.
doi:10.1371/journal.pntd.0004253.t005
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advanced and severe disease at presentation with an increased rate of multiple, large and oede-
matous lesions. Early non-ulcerative lesions (plaques or nodules) were infrequently reported.
This is not due to late presentation as in our study the time from reported symptom onset to
presentation for care was reduced in elderly patients. Instead this may be related to reduced
immunity in older populations that inhibits the control ofM. ulcerans leading to larger and
oedematous forms of disease and the dissemination of lesions to other sites. This would be sim-
ilar to the effect of HIV induced immune suppression which is associated with more severeM.
ulcerans disease with an increase in the size, number and proportion of advanced lesions[15].
The reduced immunity in elderly populations may relate to the increasing immune suppression
associated with senescence, and the increased presence of immunosuppressive conditions such
as diabetes and malignancy or the increased likelihood of receiving immunosuppressive
medication.
Our study demonstrates that treatment ofM. ulcerans disease in elderly populations is asso-
ciated with increased toxicity and reduced effectiveness. Nearly one-half (42%) of patients
aged 65 years had to cease an antibiotic due to complications at a rate 5 times higher than
younger populations, and complications were more severe with nearly one-fifth (18%) requir-
ing hospitalization. However this cannot be avoided by treating without antibiotics as treat-
ment with surgery alone resulted in a 79% increased failure rate in this age-group.
Furthermore, there is a two-fold increase in antibiotic-associated paradoxical reactions which
can cause significant morbidity and complicate treatment[11,16]. Therefore there is an urgent
need to develop less toxic and more effective treatments for elderly populations.
All of the most commonly used oral antibiotics active againstM. ulcerans have significant
drug interactions. Rifampicin induces, and ciprofloxacin and clarithromycin inhibit, the cyto-
chrome P450 enzyme system[17,18] leading to interactions with many commonly used medi-
cations. Clarithromycin and fluoroquinolones can prolong the QT interval creating a potential
for serious arrhythmias if combined with other medical conditions or medication who do the
same. This makes treatment more difficult and increases the risk of toxicity in elderly popula-
tions who are frequently prescribed multiple other medications. In addition, the pharmacoki-
netics of the antibiotics may differ with increasing age potentially resulting in toxic levels with
currently recommended doses. For example it has been shown that elderly patients have higher
serum concentrations and a longer half-life for antibiotics due to either increased bioavailabil-
ity (ciprofloxacin) and reduced renal function with age (ciprofloxacin and clarithromycin)
[19,20].
We advocate that pharmacokinetic and pharmacodynamic studies of frequently used antibi-
otics be performed in elderly patients to explore the safety and effectiveness of current and
lower doses of antibiotics, including intermittent dosing regimens (e.g. thrice weekly). Further
research should also be performed on the safety and effectiveness of shorter duration antibiotic
regimens[21]. It would be worthwhile exploring the use of alternative antibiotics such as the
new anti-tuberculous agent bedaqueline, which shows strong bactericidal activity againstM.
ulcerans in mouse models[22], and avermectins which have shown promising in vivo activity
againstM. ulcerans[23], as these may be equally effective but potentially less toxic in elderly
populations.
Elderly patients were also found to have increased rates of antibiotic-associated paradoxical
reactions, independent of lesion size. These likely occur due to the reversal of mycolactone
induced immune suppression and the increased antigenic stimulus provided by dying myco-
bacteria when antibiotics are administered[24,25]. The increased rate in elderly patients in the-
ory could relate to an increased organism load secondary to their relatively weakened immune
systems which provides a greater antigenic stimulus combined with a greater potential for
rapid immune function improvements when the inhibitory effects of mycolactone toxin are
Mycobacterium ulcerans in the Elderly
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removed with antibiotics[11]. Increased paradoxical reactions contribute to the increased tox-
icity associated with antibiotics in elderly patients, and research is required to try and under-
stand the reasons for their increased incidence in this age-group and to try and minimise their
impact. Our early experience is that pre-emptive corticosteroids commenced at the initiation
of antibiotics may prevent paradoxical reactions in elderly patients with oedematous lesions
[26] and this should be further studied.
Finally it should be noted thatM. ulcerans is not without mortality in elderly patients where
sepsis secondary to skin ulceration, or complications of treatment, can contribute to death in
patients with significant co-morbidities or frailty due to age.
We acknowledge the limitation that this is an observational study and as treatments were
not randomized between groups there may be unmeasured confounders that may have influ-
enced the results. However the cohort is large, data is collected prospectively and rates of fol-
low-up are very high supporting the validity of our findings.
In conclusion, elderly patients comprise a significant proportion ofM. ulcerans disease
patients in Australian populations and present with more severe and advanced forms of dis-
ease. Currently recommendedM. ulcerans treatments are associated with increased toxicity
and reduced effectiveness in elderly populations. Increased efforts are required to diagnoseM.
ulcerans earlier in elderly populations, and research is urgently required to develop more effec-
tive and less toxic treatments for this age-group.
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